Prevention of Rh Hemolytic Disease — Ten Years' Clinical Experience with Rh Immune Globulin

Freda, Vincent J.; Gorman, J.M.; Pollack, William; Bowe, E T

doi:10.1056/nejm197505082921906

Cited by 64 publications

(22 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This interval is not based upon any fundamental immunological observation; in fact it relates to visiting arrangements in Sing-Sing prison where some of the early studies were performed on inmate volun teers! [7]. It seems unlikely that the im munological system does delay response to an antigen for 72 h or any other arbitrary period and therefore it is more appropriate to regard the success of anti-D treatment after feto-maternal haemorrhage as due to…”

Section: Case Reportmentioning

confidence: 99%

Suppression of Early Rhesus Sensitization by Passive Anti-D Immunoglobulin

Tovey¹,

Scott²

1980

Vox Sanguinis

View full text Add to dashboard Cite

Anti-D immunoglobulin is an effective prophylactic against rhesus isoimmunization. It is generally regarded as ineffective once antibody production has developed though there have been a number of inconclusive reports suggesting it may suppress early sensitization. Anti-D (100μg) was given after delivery of a rhesus (D) positive child to a rhesus (D) negative mother who was shown to have anti-D antibodies at that time by five tests on two separate specimens in two different laboratories and by a weakly positive direct anti-globulin test on the cord blood. In a further pregnancy with a rhesus (D) positive child no antibody was detected by multiple tests including enzyme technique.

show abstract

Section: Case Reportmentioning

confidence: 99%

Suppression of Early Rhesus Sensitization by Passive Anti-D Immunoglobulin

Tovey¹,

Scott²

1980

Vox Sanguinis

View full text Add to dashboard Cite

show abstract

“…In the BDMP during 1986, an estimated 157 cases (24.8%) of all RhHDN are likely to come in contact with the health care system. (2) Rh he¬ molytic disease of the newborn is rela¬ tively easy to diagnose with current technology. (3) An RhHDN-related di¬ agnosis is likely to be found in the medi¬ cal record during abstraction.…”

Section: Resultsmentioning

confidence: 99%

“…(JAMA. 1991;265:3270-3274) Rh HEMOLYTIC disease of the new¬ born (RhHDN) is a serious and poten¬ tially fatal genetic condition.1 In 1968, Rh(D) immune globulin (Rhlg) became generally available as a public health measure for preventing perinatal mor¬ bidity and mortality due to RhHDN.2 About 90% of all cases of maternal Rh(D) sensitization and subsequent RhHDN would be eliminated if an ade¬ quate dose of Rhlg were administered to all Rh(D)-unsensitized Rh(D)-negative women pregnant with an Rh(D)-positive infant (1) after an induced or spontaneous abortion, (2) after an ectopic pregnancy, (3) after amniocentesis, (4) after antepartum placental hem¬ orrhage, (5) after transfusion of Rh(D)positive blood products, or (6) Data included in the BDMP are from all live-born and stillborn infants with diagnoses of any of 161 birth defects or genetic diseases before the first hospital discharge. Hospitals participating in the BDMP vary in size, are located throughout the United States, and are both privately and publicly owned.…”

mentioning

confidence: 99%

Epidemiology of Rh Hemolytic Disease of the Newborn in the United States

Chávez

Mulinare²,

Edmonds³

1991

JAMA

134

View full text Add to dashboard Cite

Nationwide surveillance of Rh hemolytic disease of the newborn (RhHDN) indicates that, after a substantial decline in incidence, reported rates reached a plateau in the late 1970s. We conducted a study designed to validate RhHDN surveillance data, to obtain corrected incidence estimates, and to identify potential reasons for the reported plateau. We obtained data from the Birth Defects Monitoring Program, a national surveillance system that collects data from public and private hospitals participating voluntarily. We asked hospitals for copies of the medical records for all infants discharged with a code for RhHDN and for a sample of the medical records of infants discharged with a code for other and unspecified hemolytic disease during 1986. The estimated incidence rate of RhHDN was 10.6 per 10,000 total births, with some regional variations. Our findings indicate that, despite the availability of an effective preventive measure, RhHDN continues to contribute significantly to infant morbidity and mortality in the United States.

show abstract

“…The prophylactic use of anti-Rh(D) antibody given at 28 weeks' gestation and within 72 h postpartum has result ed in the marked reduction of hemolytic disease of new born due to Rh(D) incompatibility [1,2], The coating and clearance of Rh(D)-positive fetal erythrocytes by admin istered anti-Rh(D) antibody prevents Rh immunization of the Rh(D)-negative mother. Failure of anti-Rh(D) pro phylaxis may be due to large fetomaternal transplacental hemorrhages, erroneous typing of the baby as Rh(D) negative or simply, failure to administer Rh-immune glob ulin [3],…”

Section: Introductionmentioning

confidence: 99%

Effectiveness of Four Intravenous IgG Preparations in Prevention of Phagocytosis of Anti-Rh-(D)-Coated Erythrocytes by Mononuclear Phagocytes

Sheth¹,

Al‐Sedairy²,

Lee³

1993

Vox Sanguinis

View full text Add to dashboard Cite

Four commercial intravenous immunoglobulin G (IGIV) preparations, Sand- oglobulin (Sandoz), Intraglobin (Biotest), Gammonativ (Kabivitrum) and Gammaogard (Kabivitrum) showed percent inhibition of Fc receptor-mediated phagocytosis of anti-Rh(D)-coated erythrocytes as follows: 45±14 SD, 41±23 SD, 35±14 SD, 25±13 SD, respectively. Pre-incubation of Rh(D)- positive and antibody-coated Rh(D)-positive erythrocytes with IGIV did not lead to any inhibitory effects on phagocytosis. However, preincubation of mononuclear phagocytes with IGIV gave marked inhibition of phagocytosis of antibody-coated erythrocytes. In summary, all four IGIV preparations showed Fc receptor-mediated inhibition of phagocytosis of anti-Rh(D)-coated erythrocytes by mononuclear phagocytes.

show abstract

Prevention of Rh Hemolytic Disease — Ten Years' Clinical Experience with Rh Immune Globulin

Cited by 64 publications

References 9 publications

Suppression of Early Rhesus Sensitization by Passive Anti-D Immunoglobulin

Suppression of Early Rhesus Sensitization by Passive Anti-D Immunoglobulin

Epidemiology of Rh Hemolytic Disease of the Newborn in the United States

Effectiveness of Four Intravenous IgG Preparations in Prevention of Phagocytosis of Anti-Rh-(D)-Coated Erythrocytes by Mononuclear Phagocytes

Contact Info

Product

Resources

About